Affibody Medical Investor Relations

Affibody Presents at Anglonordic Life Science


May 21, 2018

Affibody Presents at Anglonordic Life Science

Solna, Sweden, May 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Anglonordic Life Science conference, a UK and Nordic life science conference.

David Bejker, CEO, will present an overview of Affibody’s technology, key clinical assets, and upcoming value drivers on Thursday May 24 at 11:00am (GMT) at The County Hall, Belvedere Road London, UK.

We are now moving on a trajectory intended to bring us to our long term objective of creating a leading European biotech company and are excited to present the valuable milestones we expect to meet in the next twelve to eighteen months. Specifically, the key milestones related to the rapid expansion of our clinical portfolio”, said David Bejker, CEO of Affibody.

Affibody is a clinical stage Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

The company operates a focused experimental medicines model and currently has four clinical or late stage preclinical proprietary programs. The first three are therapeutic programs that targets psoriasis, B-cell driven autoimmune diseases, and liver diseases respectively. The fourth program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum.